Drugs / Cevostamab
Cevostamab
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT07831122 | Dec 2026 → Jan 2033 expected | refractory plasma cell neoplasm | Canadian Myeloma Research Group | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07629583 | Oct 2026 → Mar 2030 expected | systemic lupus erythematosus | Genentech, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07342114 | Mar 2026 → Jun 2030 expected | plasma cell myeloma | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06934044 | May 2025 → Nov 2028 expected | plasma cell myeloma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT05927571 | Aug 2023 → Jul 2027 expected | refractory plasma cell neoplasm | Genentech, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05646836 | Mar 2023 → Nov 2026 expected | plasma cell myeloma | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05137054 | Aug 2022 → Mar 2028 expected | plasma cell myeloma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT04910568 | Jul 2021 → Dec 2028 expected | plasma cell myeloma | Genentech, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT03275103 | Sep 2017 → Jan 2026 | plasma cell myeloma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05583617 | Nov 2023 → Jul 2028 expected | plasma cell myeloma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05535244 | Oct 2022 → Feb 2027 expected | plasma cell myeloma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07825064 | Oct 2026 → Apr 2029 expected | plasma cell myeloma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 2 | NCT05801939 | Jul 2023 → May 2027 expected | refractory plasma cell neoplasm | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07555938 | Jun 2026 → Oct 2028 expected | plasma cell myeloma | Hoffmann-La Roche | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2025-11-03 | Hoffmann-La Roche | Results Roche to present new data from its broad and innovative haematology portfolio at ASH 2025 roche.com ↗
Clinical and exploratory biomarker analysis from the phase Ib CAMMA-1 study shows investigational cevostamab in combination with pomalidomide and dexamethasone induces high ORR, very good partial response (VGPR) or better rates, and durable remissions, in R/R multiple myeloma. |
| 2025-11-03 | Genentech, Inc. | Results Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025 gene.com ↗
Clinical and exploratory biomarker analysis from the Phase Ib CAMMA-1 study shows investigational cevostamab in combination with pomalidomide and dexamethasone induces high ORR, very good partial response or better rates, and durable remissions, in R/R multiple myeloma. |
| 2024-11-05 | Hoffmann-La Roche | Results Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024 roche.com ↗
Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies |
| 2022-11-03 | Hoffmann-La Roche | Results Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs roche.com ↗
Positive data on cevostamab will be presented at ASH, including data from the phase I GO39775 study, which suggest that patients with heavily pre-treated multiple myeloma can maintain durable responses with fixed-duration cevostamab.11 |
| 2022-11-03 | Genentech, Inc. | Results Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs gene.com ↗
Positive data on cevostamab will be presented at ASH, including data from the Phase I GO39775 study, which suggest that patients with heavily pre-treated multiple myeloma can maintain durable responses with fixed-duration cevostamab. |
| 2020-12-08 | Hoffmann-La Roche | Results Roche presents new data from its bispecific antibody portfolio across a range of blood cancers roche.com ↗ |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-03 | Hoffmann-La Roche | Roche to present new data from its broad and innovative haematology portfolio at ASH 2025 roche.com ↗ |
| 2025-11-03 | Genentech, Inc. | Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025 gene.com ↗ |
| 2024-11-05 | Hoffmann-La Roche | Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024 roche.com ↗ |
| 2022-11-03 | Hoffmann-La Roche | Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs roche.com ↗ |
| 2022-11-03 | Genentech, Inc. | Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs gene.com ↗ |
| 2020-12-08 | Hoffmann-La Roche | Roche presents new data from its bispecific antibody portfolio across a range of blood cancers roche.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cevostamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03275103 ↗ |
| Known as | BFCR-4350A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297908 ↗ |
| Known as | RO-7187797 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297908 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4297908 ↗ |
| Route | Intravenous | “administered intravenously” NCT03275103 ↗ |